148 related articles for article (PubMed ID: 34995900)
1. Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.
Stouvenot M; Meurisse A; Saint A; Buecher B; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Smith D; Ghiringhelli F; Parzy A; de la Fouchardiere C; Almotlak H; Vienot A; Jacquin M; Taieb J; Nguyen T; Vernerey D; Borg C; Kim S
Eur J Cancer; 2022 Feb; 162():138-147. PubMed ID: 34995900
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
Kim S; Jary M; André T; Vendrely V; Buecher B; François E; Bidard FC; Dumont S; Samalin E; Peiffert D; Pernot S; Baba-Hamed N; El Hajbi F; Bouché O; Desrame J; Parzy A; Zoubir M; Louvet C; Bachet JB; Nguyen T; Abdelghani MB; Smith D; De La Fouchardière C; Aparicio T; Bennouna J; Gornet JM; Jacquin M; Bonnetain F; Borg C
BMC Cancer; 2017 Aug; 17(1):574. PubMed ID: 28841909
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
[TBL] [Abstract][Full Text] [Related]
4. Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma.
Kim S; Meurisse A; Spehner L; Stouvenot M; François E; Buecher B; André T; Samalin E; Jary M; Nguyen T; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; de la Fouchardiere C; Boulbair F; Lakkis Z; Klajer E; Jacquin M; Taieb J; Vendrely V; Vernerey D; Borg C
Ther Adv Med Oncol; 2020; 12():1758835920975356. PubMed ID: 33329760
[TBL] [Abstract][Full Text] [Related]
5. Anti-Telomerase CD4
Spehner L; Kim S; Vienot A; François E; Buecher B; Adotevi O; Vernerey D; Abdeljaoued S; Meurisse A; Borg C
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957741
[TBL] [Abstract][Full Text] [Related]
6. Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Kim S; Buecher B; André T; Jary M; Bidard FC; Ghiringhelli F; François É; Taieb J; Smith D; de la Fouchardière C; Desramé J; Samalin E; Parzy A; Baba-Hamed N; Bouché O; Tougeron D; Dahan L; El Hajbi F; Jacquin M; Rebucci-Peixoto M; Spehner L; Vendrely V; Vernerey D; Borg C
BMC Cancer; 2020 Apr; 20(1):352. PubMed ID: 32334548
[TBL] [Abstract][Full Text] [Related]
7. DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma.
Kim S; Jary M; Mansi L; Benzidane B; Cazorla A; Demarchi M; Nguyen T; Kaliski A; Delabrousse E; Bonnetain F; Letondal P; Bosset JF; Valmary-Degano S; Borg C
Ann Oncol; 2013 Dec; 24(12):3045-50. PubMed ID: 24114858
[TBL] [Abstract][Full Text] [Related]
8. [Squamous cell anal carcinoma. What's next ?].
Kim S; Spehner L; Cabel L; Bidard FC; Borg C
Bull Cancer; 2021 Jan; 108(1):80-89. PubMed ID: 33423780
[TBL] [Abstract][Full Text] [Related]
9. Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen.
Sendur MA; Ozdemir N; Özatlı T; Yazıcı O; Aksoy S; Ekinci AS; Yazılıtaş D; Günaydın Y; Oksuzoglu B; Benekli M; Zengin N
Med Oncol; 2014 Sep; 31(9):153. PubMed ID: 25099765
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Disease Control After locoregional Pelvic Chemoradiation in Patients with Advanced Anal Squamous Cell Carcinoma.
Grave A; Blanc J; De Bari B; Pernot M; Boulbair F; Noirclerc M; Vienot A; Kim S; Borg C; Boustani J
Front Oncol; 2022; 12():918271. PubMed ID: 35936677
[TBL] [Abstract][Full Text] [Related]
11. [Metastatic squamous cell carcinomas of the anal canal: Current management and prospects].
Saint A; Evesque L; François É
Bull Cancer; 2020; 107(7-8):792-799. PubMed ID: 32591138
[TBL] [Abstract][Full Text] [Related]
12. Mitomycin and 5-fluorouracil for second-line treatment of metastatic squamous cell carcinomas of the anal canal.
Saint A; Evesque L; Falk AT; Cavaglione G; Montagne L; Benezery K; Francois E
Cancer Med; 2019 Nov; 8(16):6853-6859. PubMed ID: 31524335
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
[TBL] [Abstract][Full Text] [Related]
14. Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab.
Khawandanah M; Baxley A; Pant S
J Oncol Pharm Pract; 2015 Jun; 21(3):232-7. PubMed ID: 24627343
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerance of cetuximab in combination with 5 FU plus irinotecan based chemotherapy in metastatic squamous cell anal carcinoma.
Valery M; Cervantes B; Smolenschi C; Boilève A; Boige V; Malka D; Hollebecque A; Ducreux M
Dig Liver Dis; 2023 Mar; 55(3):407-411. PubMed ID: 36088220
[TBL] [Abstract][Full Text] [Related]
16. New approaches in palliative systemic therapy of anal squamous cell carcinoma.
Lohynská R; Pechačová Z
Klin Onkol; 2022; 35(3):190-194. PubMed ID: 35760571
[TBL] [Abstract][Full Text] [Related]
17. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal.
Eng C; Chang GJ; You YN; Das P; Rodriguez-Bigas M; Xing Y; Vauthey JN; Rogers JE; Ohinata A; Pathak P; Sethi S; Phillips JK; Crane CH; Wolff RA
Oncotarget; 2014 Nov; 5(22):11133-42. PubMed ID: 25373735
[TBL] [Abstract][Full Text] [Related]
18. Multimodal Therapy of Squamous Cell Carcinoma of the Anus With Distant Metastasis: A Single-Institution Experience.
Evesque L; Benezery K; Follana P; Tuan Falk A; Doyen J; Reure J; Cavaglione G; François E
Dis Colon Rectum; 2017 Aug; 60(8):785-791. PubMed ID: 28682963
[TBL] [Abstract][Full Text] [Related]
19. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
[TBL] [Abstract][Full Text] [Related]
20. [Effects of radical radiotherapy combined with different regimens of chemotherapy on radiation intestinal injury in patients with non-metastatic anal squamous cell carcinoma].
Pang XL; Liu S; Liu YP; Chen HY; He F; Zheng J; Wan XB
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):977-983. PubMed ID: 34823298
[No Abstract] [Full Text] [Related]
[Next] [New Search]
